Welcome to our dedicated page for Bwx Technologies news (Ticker: BWXT), a resource for investors and traders seeking the latest updates and insights on Bwx Technologies stock.
BWX Technologies Inc (BWXT) delivers mission-critical nuclear components and technical services for government and commercial sectors worldwide. This dedicated news hub provides investors and industry professionals with authoritative updates directly from the company and verified sources.
Access real-time announcements including earnings reports, government contract awards, and R&D breakthroughs in nuclear manufacturing. Track developments across BWXT's core operations: precision component production for defense programs, radiopharmaceutical innovations, and environmental remediation projects.
Our curated feed simplifies monitoring of strategic partnerships, regulatory milestones, and technology advancements in nuclear operations. Bookmark this page for streamlined access to BWXT's official financial disclosures, facility updates, and leadership communications - all essential for understanding this specialized industrial leader.
BWX Technologies, Inc. (NYSE: BWXT) will release its first quarter 2023 results on May 8, 2023, after market close, followed by a conference call at 5:00 p.m. EDT. Investors can participate via a listen-only format and view a supporting presentation on the company’s website. For dial-in participation, the U.S. number is 1-833-470-1428 and the international number is 1-929-526-1599 with access code 698120. BWXT, a Fortune 1000 and Defense News Top 100 company, is headquartered in Lynchburg, Virginia. It specializes in nuclear solutions for security, clean energy, and environmental restoration with approximately 7,000 employees and 14 operating sites across the U.S., Canada, and the U.K.
BWX Technologies (NYSE: BWXT) announced a significant engineering contract with GE Hitachi Nuclear Energy for the BWRX-300 small modular reactor (SMR) reactor pressure vessel (RPV). The RPV, crucial for the reactor core, will undergo engineering analysis, design support, and manufacturing preparations. This contract highlights BWXT's engineering strengths and supports increasing interest in SMR development across North America and Europe. The BWRX-300 is projected to have lower capital costs per MW compared to other SMR designs, enhancing its market viability. Forward-looking statements caution about potential risks like project delays and modifications.
BWX Technologies, Inc. (BWXT) reported Q4 2022 diluted GAAP EPS of $0.47, down 63% from $1.26 a year ago, with revenue of $624.2 million, a 5% increase year-over-year. For the full year, GAAP EPS decreased by 20% to $2.60, while adjusted EBITDA rose to $439.4 million. Operating cash flow for 2022 was $244.7 million. The company declared a quarterly cash dividend increase to $0.23 per share, payable on March 28, 2023. Despite solid results, labor market challenges are expected to hinder growth in 2023. BWXT's 2023 guidance estimates revenue of ~$2.4 billion and adjusted EBITDA of ~$475 million.
Ontario Power Generation's Darlington Nuclear Generating Station has successfully installed a new isotope system, enabling the production of life-saving Molybdenum-99 (Mo-99) isotopes, a first for a commercial reactor. This innovative production will help alleviate the long-standing shortages of Mo-99, crucial for generating Technetium-99m, a primary diagnostic imaging agent in nuclear medicine. The project, a collaboration between Laurentis Energy Partners and BWXT Medical Ltd., awaits final regulatory approvals from the FDA and Health Canada before commercial production begins. The facility can produce enough Mo-99 to meet a significant portion of North America's demand.
BWX Technologies, Inc. (NYSE: BWXT) will release its fourth quarter and full-year 2022 results on February 23, 2023, post-market. A conference call is scheduled for 5:00 p.m. EST, enabling listeners to join and view the presentation online. BWXT is headquartered in Lynchburg, Virginia, and is recognized as a leading innovator in nuclear solutions, serving sectors including global security and clean energy. The company has approximately 6,700 employees and operates major sites throughout the U.S., Canada, and the U.K., contributing to its critical roles in projects for the U.S. Department of Energy and NASA.
Fusion Pharmaceuticals Inc. and BWXT Medical have announced a preferred partner agreement for the supply of actinium-225, vital for targeted alpha therapies. This agreement ensures Fusion's access to high-purity actinium needed for its expanding clinical pipeline, which includes three proprietary programs in trials. BWXT Medical, a leader in medical isotopes, will provide actinium at volume-based pricing, enhancing Fusion's supply chain and supporting future growth. The collaboration aims to meet the growing demand for effective cancer treatments utilizing alpha-emitting isotopes.
Fusion Pharmaceuticals and BWXT Medical have established a preferred partner agreement for the supply of actinium-225, enhancing Fusion's existing isotope supply for its clinical-stage radiopharmaceuticals. This strategic partnership is poised to support growing demand for targeted alpha therapies (TATs) while ensuring volume-based pricing. The collaboration emphasizes BWXT's commitment to meeting the global actinium supply needs, bolstering Fusion's clinical programs and future business opportunities.
BWX Technologies, Inc. (NYSE: BWXT) announced the promotion of Ronald O. (Chip) Whitford, Jr. to senior vice president, general counsel, and chief compliance officer, effective January 2, 2023. He succeeds Thomas E. McCabe, who will transition to a special advisor role until his retirement on August 1, 2023. Whitford, with a background in legal affairs spanning multiple industries, has been with BWXT since 2017. This move is part of the company’s succession planning strategy, ensuring continuity in its legal and compliance functions.
BWX Technologies (NYSE: BWXT) has marked a significant breakthrough with the production of TRISO nuclear fuel, celebrated alongside officials from the U.S. Department of Defense, Department of Energy, NASA, and Idaho National Laboratory. This fuel, noted for its robustness, will power the first U.S. microreactor under Project Pele with a $37 million grant from Idaho National Laboratory. BWXT aims to enhance energy resilience, enabling clean energy objectives and support for military and disaster responses.
